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ABSTRACT 
Introduction: The 2016 World Health Organization (WHO) consolidated guideline 
recommends lifelong antiretroviral therapy (ART) for all HIV-infected pregnant and 
breastfeeding women for preventing mother-to-child HIV transmission (PMTCT). Ambiguity 
remains about the cost-effectiveness of this strategy in resource-limited developing countries.  
Areas Covered: We reviewed model-based studies on the cost-effectiveness of lifelong ART 
(formerly Option B+) relative to previous WHO guidelines for PMTCT. Our search using 
PubMed, Medline and Google Scholar for articles on Option B+ resulted in the final inclusion 
of seven studies published between 2012 and 2016. The Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) checklist was used to assess the quality of 
reporting. Outcomes of interest, which included infant infections averted, maternal quality and 
length of life, and the Incremental Cost Effectiveness Ratio (ICER), were used in comparing 
cost-effectiveness.  
Expert Commentary: Despite most model-based studies favouring lifelong ART (Option B+) 
in terms of cost-effectiveness in comparison to Options A and B, inclusiveness of the evidence 
remains weak for generalization largely because setting specificity for providing lifelong ART 
to all pregnant and breastfeeding women may differ significantly in each setting. Therefore, 
future cost-effectiveness studies should be robust, setting-specific, and endeavor to assess the 
willingness and ability to pay of each setting. 
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1. INTRODUCTION 
Every year, an estimated 1.4 million women living with HIV become pregnant [1]. The 
majority of these women are based in sub-Saharan Africa where approximately 4,500 new HIV 
infections among young women occurred every week [2]. Realizing that achieving an HIV-
free era means eliminating transmission, the global community embarked on an ambitious plan 
to  attain zero new HIV infections among infants born from infected women by 2020 [3]. In 
2015, it was reported that about 83% of the estimated 150,000 children newly infected with 
HIV were in eastern and southern Africa where coverage of antiretroviral therapy (ART) 
among HIV-infected pregnant women was about 79% (range 70-88%) [4]. Despite significant 
gains recently made in reducing the number of children dying from HIV/AIDS-related illness 
by 62% [5] and the increase in treatment coverage in sub-Saharan Africa, where an estimated 
13.8 million people were receiving ART at the end of 2016 [6] compared with only 50,000 a 
decade earlier [7], transmission from mother-to-child remains quite widespread.  
 
Prevention of mother-to-child transmission (PMTCT) programs have been implemented 
worldwide primarily aimed at eliminating transmission of HIV to children born from HIV-
infected mothers. Over the years, PMTCT guidelines from the World Health Organization 
(WHO) have evolved over several iterations [7, 8] (Table 1). The most recent 2016 WHO 
guideline recommends initiating upon diagnosis, life-long ART with tenofovir, lamivudine (or 
emtricitabine) and efavirenz among all HIV-positive pregnant and breastfeeding women 
regardless of CD4 count or clinical staging [9]. This presents a shift from the previous WHO 
recommendations which provided optional strategies [7].  
Table 1: Evolution of WHO PMTCT recommendations. Key: AZT = Zidovudine, sdNVP = 
single dose Nevirapine, NVP = Nevirapine, 3TC = Lamivudine 
 
PMTCT 
Guideline 
Recommendation for preventing HIV transmission 
 
Treatment 
Initiation 
Threshold 
Year 
Strategy 
Launched Mother: Infant: 
Option A 
[10] 
If breastfeeding: Daily AZT 
commenced at 14 weeks gestation 
(Antepartum) then sdNVP + 
AZT/3TC at onset of labor 
(Intrapartum) then AZT/3TC 
continued for 7 days (Postpartum) 
OR 
If not breastfeeding: AZT with 
sdNVP before and during delivery 
with either AZT, or NVP for 6 
weeks postpartum  
If breastfeeding: NVP daily 
from birth upto 7 days after 
cessation of breastfeeding. 
CD4 <350 
cells/µL 
2006 
Option B 
[10] 
If breastfeeding: Triple ARVs from 
14th week of pregnancy up to one 
week after cessation of 
breastfeeding; 
OR 
If not breastfeeding: Triple ARV 
drug therapy administered from 14th 
week of pregnancy until delivery.  
Irrespective of feeding 
method: NVP or AZT daily 
from birth upto 4 ± 6 weeks 
CD4 <500 
cells/µL 
2010 
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Option B+ 
[10] 
ART for all pregnant and 
breastfeeding women regardless of 
CD4 count or WHO clinical staging 
Irrespective of feeding 
method: NVP or AZT daily 
from birth upto 4 ± 6 weeks 
As soon as 
diagnosed  
2013 
µ7HVW	
7UHDW$OO¶ 
[9] 
Lifelong ART for all pregnant and 
breastfeeding women regardless of 
CD4 count or WHO clinical staging 
Irrespective of feeding 
method: AZT and NVP daily 
from birth upto 6 weeks 
As soon as 
diagnosed 
2016 
 
Notwithstanding the current WHO recommendation of life-long ART (previously referred 
to as Option B+), the prior PMTCT guidelines remain in use in a number of settings yet to 
make the transition [11]. However, each of these particular PMTCT guidelines tends to give 
isolated and conflicting evidence in favor of any given strategy, showing each of them to be 
efficacious. For instance, available evidence suggests Option A and B regimens for PMTCT 
had similar efficacy in clinical trial settings [12, 13, 14, 15]. Aside this evidence, there has been 
insufficient head-to-head comparison on cost-effectiveness of the respective strategies in 
resource-limited settings. This is a concern for key decision makers in most low- and middle-
income countries (LMICs) in sub-Saharan Africa WKDWDUHPDNLQJWKHWUDQVLWLRQWRµWHVW	WUHDW
DOO¶. 
 
Resource scarcity is an important consideration in LMICs, with up to 70% of healthcare 
expenditures spent on medicines, much of which is out-of-pocket [16, 17]. Healthcare policy 
makers in LMICs are concerned with establishing not only that a change in treatment protocol 
is justified through being more clinically effective, but also concerned about the extra costs 
incurred. Across countries, healthcare payers aim to maximize health outcomes within their 
constrained resources [18], which includes striving to provide, or continuing to provide, 
universal healthcare [17, 19, 20, 21]. Consequently, in order to have an efficient strategy that 
ensures value for money, a number of health-economic evaluations of available strategies have 
been conducted and published. These analyses have mainly been based on decision analytic 
modeling - a systematic approach to decision-making under conditions of uncertainty through 
the use of mathematical relationships to define a series of consequences resulting from all 
possible alternatives [22].  
 
Deviation from the methods of health-economic evaluation and decision analytic modeling 
can influence the validity and generalizability of any findings, with the methods and 
assumptions having profound effects on the findings and consequently on payerV¶ decisions 
[22]. In the studies reviewed in this paper, several assumptions were made in their models. For 
instance on fertility, Gopalappa et al [23] assumed that between ages 15 ± 49, each woman in 
Kenya, Zambia, South Africa and Vietnam gave birth to between 2 to 6 children, respectively. 
In Zimbabwe, among several assumptions made, Ciaranello et al [24] assumed there was 100% 
adherence to their PMTCT regimens among all women identified as HIV-positive on their first 
antenatal visit. A similar assumption was taken by Ishikawa et al [25] in Zambia. Therefore, it 
is important that assumptions and results be consistent across jurisdictions. Whereas a recent 
review of model-based cost-effectiveness analyses in developing countries by Karnon and Orji 
[18] suggested that Option B+ was likely to be cost-effective relative to other PMTCT 
strategies (as adjudged from one comprehensive analysis across five model-based studies 
reported), their findings are yet to be corroborated. Importantly, their review highlighted that 
some evaluations omitted potentially important additional benefits. Consequently, they 
concluded that additional model analyses are required. This review aimed to provide additional 
perspectives pertaining to the health-economic evaluation of lifelong ART (Option B+) 
strategy relative to other WHO recommendations in order to give guidance to decision-makers 
in sub-Sahara African countries and other LMICs seeking to improve the management of HIV 
patients within limited resources. 
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2. METHODS 
2.1. Literature search 
We conducted a literature search using PubMed, Medline and Google Scholar databases 
to identify original publications. As lifelong ART (Option B+) for PMTCT was a relatively 
new strategy, the search period was not limited but included all available articles published on 
the subject search criteria so far prior to this review. An initial search for titles and abstracts 
published in English was conducted in April 2017 using the search terms: µ2SWLRQ%25
PMTCT (Cost-effectiveness OR Cost-Utility OR Cost benefit OR Economic OR Cost) AND 
3UHYHQWLRQ RI 0RWKHU WR &KLOG 7UDQVPLVVLRQ 25 +,9¶ )XUWKHUPRUH UHIHUHQFH OLVWV RI WKH
identified studies and reviews were searched manually. 
 
2.2. Study selection 
Using methods of identification, screening, eligibility and inclusion of published records 
described by Moher et al. [26], full text retrieval was subsequently undertaken and subjected 
to the inclusion and exclusion criteria. Non-model-based evaluation studies were excluded. Out 
of the possible publications initially identified in the literature search (n=1038), a total of seven 
studies that met the selected search criteria were included. Details of the review process are 
shown in figure 1. 
 
 
2.3. Data Extraction and Quality Assessment 
The publication related characteristics of each study were extracted (Table 2). The 
characteristics included: Author, publisher/journal, country, perspective, outcome measure, 
time horizon, model type and funders. The outcome of cost-effectiveness, such as the 
Incremental Cost Effectiveness Ratio (ICER) was extracted as reported without making any 
adjustments for the year, exchange rate or purchasing power parity employed. The 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) [27] was used to 
assess the quality of reporting of the published papers.  
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3. RESULTS 
 
3.1. Quality Assessment 
Based on the 24-item CHEERS checklist criteria (Available online URL: 
http://www.equator-network.org/wp-content/uploads/2013/04/Revised-CHEERS-Checklist-
Oct13.pdf [9]), most studies had good reporting quality with respect to sensitivity analyses, 
perspectives, time horizons, methods, and limitations in main body of the publication.  
 
3.2. Overview of included studies 
The publication year for the seven included studies ranged from 2012 to 2016. Most of 
these studies were country-specific model-based economic evaluations. Only one study [23] 
investigated more than one country. A healthcare system (payer) perspective was taken in all 
the studies, although this was not explicitly stated in some. Infant infections averted was the 
most common outcome measure amongst all the studies. Whilst two studies [25, 28] applied a 
fixed time horizon of 10 years, the other studies  applied a lifetime horizon [24, 29, 30]. Most 
of the studies were funded by medical research agencies such as the National Institute for 
Health (NIH) and non-profit organizations such as Bill & Melinda Gates Foundation and 
Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), respectively. None of the studies were 
funded by the pharmaceutical industry. Only one study [31] had the lead author affiliated to a 
pharmaceutical company. The study characteristic overview is summarized in Table 2.  
 
The primary population of interest in most studies was HIV-positive pregnant women and 
their infants. However, some of the studies modeled the life and HIV risk of all women of 
child-bearing age [30]. Quality-adjusted life years (QALYs) were a complementary outcome 
measure in two studies [23, 30] . The QALY being a generic measure of health aims to reflect 
WKHLPSDFWRILQWHUYHQWLRQVRQLQGLYLGXDOV¶OHQJWKRIOLIHDQGKHDOWK-related quality of life in a 
single measure [32]. Only three studies used the Disability-Adjusted Life Year (DALY) - a 
measure of disease burden [30]. Although the DALY is relatively common in economic 
evaluations, it differs from QALY in many aspects. Historically, QALYs have been used more 
often for pricing, reimbursement, and funding decisions [20, 33, 34]. 
 
3.3. Review of Specific Studies 
Ciaranello et al [24] evaluated the clinical impact, cost and cost-effectiveness of the 
different WHO-recommended PMTCT guidelines in Zimbabwe. These guidelines, as stated 
before, started as early as 2013 advocating for the initiation of lifelong ART among all HIV-
positive pregnant women, regardless of CD4+ cell count. In this study, three validated and 
linked computer models were used to simulate a cohort of HIV positive pregnant women. One 
of the linked models was the Mother-to-Child HIV transmission model, which modeled a single 
pregnancy and delivery. The other two were both Cost Effectiveness of Preventing AIDS 
Complications (CEPAC) models, which included: the CEPAC infant model - a model of HIV 
infection and mortality among breastfed infants; and the CEPAC adult model in which HIV 
progression among postpartum women was modeled [24]. The study population mean age was 
24 years, mean CD4 count was 451 cells/mm3 and assumed pregnant women to present for 
their first antenatal care visit at 24-28 weeks of pregnancy. A subsequent breastfeeding period 
of 18 months was considered. The simulated interventions were: no treatment, single-dose 
nevirapine (sdNVP); WHO Option A; Option B; and Option B+, respectively. The outcomes 
considered by Ciaranello et al were infant and maternal Life Expectancy (LE) and lifetime 
healthcare costs using the 2008 US dollar (US$) costing and prices. Although the reported costs 
excluded non-drug related costs of providing ART, the impact of implementation costs in the 
antenatal period was examined. 
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Overall, the study by Ciaranello et al found that among infants born to HIV-infected 
women, Options B and B+ had similarly lower pediatric HIV infection rates (5.7%) as 
compared to Option A (7.5%), sdNVP (14.2%) and no antenatal treatment (24.8%), 
respectively [24]. The projected undiscounted Life Expectancy (LE) (including HIV infected 
and non-infected infants) ranged from 38.35 years (with no antenatal ARVs) to 44.18 years 
(with Option B and B+) respectively. Over longer time horizons, the undiscounted lifetime 
costs per infant ranged from US$ 730 (with no antenatal ARVs) to US$ 350 (with Options B 
and B+). The authors argued that PMTCT regimens that prevented more infant infections also 
led to lower lifetime healthcare costs [24]. In terms of projected maternal LE from delivery, 
there was a paradox in that µno treatment¶ had a better outcome (21.25 years) than sdNVP 
(20.94 years). They attributed this to impact of resistance to non-nucleotide reverse 
transcriptase inhibitors on follow-up of first-line ART. The other interventions; Options A, B 
and B+ had 21.26, 21.30 and 22.42 years respectively. Clearly, the differences in projected 
maternal LE were quite insignificant across the interventions, except for Option B+ which 
recorded a gain in LE greater than 1.0 years compared to options A and B. In the long run, 
maternal costs were found to be similar for µno antenatal ARVs¶, sdNVP and Option A. In 
terms of costs, Option B and B+ had undiscounted costs of US$ 8450 and US$ 9820, 
respectively. Their findings favored Option B+ as the more cost-effective option followed by 
Option B. However, the authors postulated that Option B had deleterious effects following the 
interruption of treatment. Additionally, univariate and multivariate sensitivity analyses were 
conducted to show how robust the findings were to the assumption. The parameters subjected 
to sensitivity analyses included access to antenatal and postnatal care with a focus on key 
PMTCT, pediatric, maternal and cost parameters [24]. In their study, even with an assumed 
reduced access to PMTCT services or access to CD4 testing, Option B remained less costly 
and more effective than no treatment, sdNVP, and Option A. The ICER of Option B+ compared 
to Option B also remained similar at US$ 1370 per Life Year Saved (LYS). However, under 
the reported rates of Lost to Follow-Up (LTFU) from maternal postnatal HIV care, the ICER 
reduced to US$ 850 per LYS. Under clinical parameters, when the risk of virological failure 
was altered to 1.5 times higher than the base case, Option B did not dominate Option A; but 
when increased two-fold, Option A dominated Option B. Nonetheless, policy conclusions 
remained the same.  
 
Fasawe et al [28] conducted a cost-effectiveness study of the standard of care for PMTCT 
(i.e. current practice in 2010 versus WHO recommended Options A, B and B+ for PMTCT) in 
Malawi. A decision tree and Markov model was used in this study. The authors analyzed an 
annual cohort of 66,500 pregnant women diagnosed with HIV on their first antenatal visit and 
simulated a 10-year time horizon. In the Markov model, women transitioned between four 
states based on the CD4 count and death as the absorbing state. Outcomes measured by Fasawe 
et al were similar to Ciaranello et al except for an inclusion of DALYs. Cost per infant HIV 
infection averted, maternal life year gained and DALYs were assessed. According to Fasawe 
et al, Option A was found to avert less infections and cost less than options B and B+, 
respectively [28]. The reported ICER for Option A, B and B+ was US$ 844, US$ 1,331 and 
US$ 1,265 per infection averted respectively. Furthermore, the ICER for options A, B and B+ 
were US$ 37, US$ 60 and US$ 57 per DALY averted, respectively. Nevertheless, using the 
ICER comparing to the current practice as the base case, Option A turned out to be cost-
effective with an ICER of US$ 38, whereas Options B and B+ had US$ 68 and US$ 64 per 
infection averted, respectively. Regarding ten-year maternal survival rates which they reported 
improved more than four-fold with Option B+, Fasawe et al reported an ICER per life year 
gained of US$ 341, US$ 338 and US$ 455 for Options A, B and B+ respectively, all relative 
to the current practice. Everything else being equal, including universal CD4 testing 
availability, Option A remained cost-effective according to their study. From the one-way 
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sensitivity analyses they performed, arguably Option A had lower ICER versus current practice 
with alteration to the cost, efficacy of ARVs and transmission rates only that it had a lower 
ICER versus current practice. Accordingly, for Options B and B+ to attain a lower ICER 
compared to Option A, the cost of ART had to reduce by up to 40% and only if the coverage 
of CD4 count testing was lower than 73% in Malawi [28]. However, if Options B and B+ led 
to a larger increase in DALYs, this may merely imply both strategies have a higher ICER than 
Option A and not necessarily that either LVµOHVVFRVW-HIIHFWLYH¶ 
  
Tweya et al [29] evaluated the cost-effectiveness of Option B+ (lifelong ART) relative to 
Option B in Malawi. Their study used an individual-based simulation model to simulate 10 000 
women and their infants. First and second pregnancy outcomes were modeled. Following the 
first pregnancy, the infant infection rate was similar for both Options B and B+ at 15%. At the 
start of the second pregnancy, more women were on lifelong ART (Option B+) at 39% as 
compared to only 18% on Option B. However, the rate of infant infection only differed by 1% 
(11.3% for Option B+ and 12.3% for Option B). The ICER of lifelong ART (Option B+) 
compared with Option B per DALY averted range was US$ 500 to US$ 1300. The study 
concluded that lifelong ART (Option B+) was cost-effective compared to Option B as it was 
associated with a lower ICER with regards to averting infections during the second pregnancy, 
having taken into account the total future costs and lost lifetime of the infected infants.   
 
Similarly, VanDeusen et al [30] evaluated the cost-effectiveness of lifelong ART (Option 
B+) compared to Option B in multiple pregnancies in Ghanaian women. They used a state- 
transition model to compare lifetime costs and health benefits associated with the two strategies 
for PMTCT. The outcomes measured were infant HIV infections averted, life expectancy and  
QALYs. When discounted lifetime costs were compared, Option B cost US$ 6,254 and lifelong 
ART (Option B+) cost US$ 12,624, respectively. Despite Option B+ being more costly 
compared to Option B, it yielded a substantial gain in QALYs over Option B. The reported 
ICER for Option B+ was US$ 785 per QALY gained or US$ 618 per life-year gained, assuming 
maternal and infant quality-of-life weights were ignored. Their cost-effectiveness analysis 
showed that even when the annual cost of HIV care increased 1.5-fold in Ghana, the ICER 
remained below the FRXQWU\¶VJURVVGRPHVWLFSURGXFW (GDP) per capita. VanDeusen et al also 
concluded in favor of lifelong ART (Option B+) being cost-effective as compared to Option B 
in resource-limited countries.   
 
A deterministic model was used by Gopalappa et al [23] to determine the costs and benefits 
of lifelong ART (Option B+) versus Options A and B for PMTCT. Four countries included in 
the evaluation were Kenya, South Africa, Vietnam and Zambia. The model used simulated 
births, breastfeeding, and HIV infection in women. The outcomes were infant infections 
averted and partner sexual transmissions averted by ART. Gopalappa et al found lifelong ART 
(Option B+) to be cost-effective compared to Options A and B, respectively. For instance, 
considering total cost per total mother-to-child and sexual transmissions averted, Option B+ 
was found to be cost-saving compared to µno PMTCT¶, Options A and B in all four countries. 
They also considered the cost of PMTCT per child infection averted for Option A versus Option 
B+ after KDYLQJ HOLPLQDWHG WKH VWURQJO\ GRPLQDWHG µ1R 307&7¶ DQG 2SWLRQ % DUP IURP
subsequent cost-effectiveness analysis. Provided that ART eligibility was CD4+ cell count less 
than 350 cells/µl, lifelong ART (Option B+) incurred an additional cost of approximately US$ 
6,000, US$ 6,800, US$ 23, 000, and US$ 21, 500 per infant infection averted in Kenya, Zambia, 
South Africa, and Vietnam, respectively, compared with Option A.. However, if ART 
eligibility was expanded to a CD4+ cell count less than 500 cells/µl, lifelong ART (Option B+) 
would incur an additional cost of approximately US$ 6,300, US$ 7,200, US$ 13,500 and US$ 
9,800 per infant infection averted in the four countries, respectively, compared with Option A 
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[23]. The authors highlighted the limitations of this simple deterministic model in the 
discussion. 
 
Ishikawa et al [25] used a decision analytic model to conduct an economic evaluation of 
the 2010 and 2013 WHO recommendations for PMTCT in Zambia. The comparators in this 
study were options A, B and B+. The outcomes of interest were infant and partner infections 
averted, as well as changes in QALYs. An ICER per infection averted and QALY were also 
calculated. The study reported a 33% reduction in infant infections in favor of 2013 WHO 
guidelines (Options B and B+). In terms of partner infections averted for serodiscordant 
couples over a 10 year time horizon, the risk of HIV transmission reduced by 72% following a 
shift from Option A to Option B, and further reduced by  15% when shifting from Option B to 
Option B+. All these findings were based on an annual cohort of 600 000 pregnant women with 
an HIV rate of 16.1% [25]. The ICER was found to be US$ 1,034, US$ 1,140 and US$ 1,406 
per infant infection averted for Options A, B and B+, respectively. Taking into consideration 
the partner infections averted, the ICER reduced to US$ 1,023 and US$ 1,254 for Option B and 
lifelong ART (Option B+), respectively. The ICER per QALY gained due to infant infections 
averted was reported to be US$ 88 and US$ 155 for Option B and lifelong ART (Option B+), 
respectively. Taking into consideration the partner infections averted, the ICER per QALY was 
found to be US$ 77 and US$ 132 for Option B and lifelong ART (Option B+) respectively. In 
terms of cost-effectiveness over a 10-year time horizon, , Options B and B+ appeared to have 
been dominant. A sensitivity analysis was conducted on the access and utilization of health 
services, discordance rate, and HIV prevalence, in order to examine the robustness of the 
findings. Option B and lifelong ART (Option B+) remained cost-effective at altered access and 
utilization of health services. Under an altered discordance rate, Option B remained the 
dominant strategy compared to Option A. In addition, at discordance rates of 40% and 5%, 
lifelong ART (Option B+) was dominant and cost-effective respectively. 
 
Kuznik et al [31] evaluated the cost-effectiveness of 18-months ART and life-long ART 
relative to that of other alternative strategies (sdNVP, dual ARV therapy or no treatment) for 
PMTCT in Uganda. A two-phased decision-based analytic model, which focused on multiple 
pregnancies and infant outcomes, was developed. This study only considered one clinical 
outcome of mother-to-child transmission and estimated the associated DALYs based on HIV-
attributable life expectancy as well as disability weights for HIV infection and AIDS. The study 
focused on ART eligible women based on their CD4 count. Costs considered for ART included 
drug acquisition costs and other healthcare utilization services such as physician and laboratory 
visits. However, for sdNVP and dual ARV therapy, only drug acquisition costs were 
considered. The cost per DALY for lifetime ART when compared to sdNVP, dual ARV 
therapy, and no therapy were US$ 205, US$ 354 and US$ 172, respectively. In the same vein, 
18-months ART (Option B) averted fewer DALYs but at a lower cost. The DALYs averted in 
Option B were 5.21, 3.22, and 8.58 when compared to sdNVP, dual therapy and no treatment, 
whereas the cost per DALY was US$ 46, US$ 99 and US$ 34, respectively. 
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Author Publisher/ 
Journal 
Country Perspective Outcome measures Time 
Horizon 
Key Results 
Ciaranello et al. 
(2013) [24] 
Clinical 
Infectious 
Diseases 
Zimbabwe Healthcare 
(Payer) 
Infant infections averted, 
maternal and infant LE, 
healthcare costs 
Lifetime Option B+ improved maternal and infant health 
benefits (LE, 39.04 years; lifetime cost, 
US$6620 per mother±infant pair), with an ICER 
of US$1370 per YLS compared with Option B. 
Fasawe et al. 
(2013) [28] 
PLoS ONE Malawi Healthcare 
system (Payer) 
Averted infant infection, DALYs, 
maternal life years gained 
10 years Option B+ not only prevented infant infections, 
but improved maternal survival more than four-
fold saving more than 250,000 maternal life 
years, as compared to Option A or B. Option 
B+ yielded favourable ICER of US$ 455 per 
life year gained over the current practice. 
Gopalappa et al. 
(2014) [23] 
AIDS. Wolters 
Kluwer Health 
Kenya, South 
Africa, 
Vietnam, 
Zambia 
Healthcare 
system 
Child infections averted, PMTCT 
costs 
Lifetime Option B+ averted more child infections 
compared with Option B in all four countries. 
Option B+ was the most cost-effective strategy 
costing between US$6000 and US$23 000 per 
infection averted compared with Option A. 
Ishikawa et al. 
(2013) [25] 
PLoS One Zambia Healthcare 
system 
QALY, Infant and Serodiscordant 
Partner and infections averted 
10 years Shift from Option A to Option B+ resulted in 
33% HIV risk reduction among exposed infants, 
87% among serodiscordant partners.  
Tweya et al. 
(2016) [29] 
AIDS. Wolters 
Kluwer Health 
Malawi Healthcare 
system 
DALY, Infant infection averted, 
healthcare costs (antenatal, 
postnatal & lifetime) 
Lifetime Comparing Option B+ and Option B, ICER 
ranged between US$500 and US$1300 per 
DALY averted. 
VanDeusen et al 
(2015) [30] 
BioMed Central Ghana Healthcare 
system 
QALY, Infant infection averted, 
ICER 
 
Lifetime Option B+ theoretically prevented up to 668 
infant infections annually. Despite higher initial 
ART costs, Option B+ cost US$785/QALY 
gained. 
Kuznik et al. 
(2012) [31] 
Bull. WHO Uganda Healthcare 
system 
DALY, Infant infections averted 
 
Lifetime Compared to other PMTCT options, lifetime 
ART (Option B+) averted  
 19.20, 11.87 and 31.60 DALYs at a cost of US$ 
205, US$ 354 and US$ 172 per DALY averted. 
 
Table 2: Reviewed studies, notable outcomes measures and key results 
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3.4. Key Drivers of Cost-effectiveness 
Based on our review, the key drivers of cost-effectiveness identified in the studies 
included: fertility rate, birth interval, comparative ART eligibility (based on CD4+ count), 
infant infections averted, partner infections averted, fertility and live birth intervals. Others 
included: ART regimen effectiveness, life expectancies, access to antenatal (and postnatal) 
care, disease transmission probabilities, and increased future healthcare benefits versus costs 
for infected infants. As highlighted by VanDeusen et al [30], as the likelihood of accessing 
antenatal care positively increases to over 90% in the developing countries, lifelong ART 
(Option B+) becomes more cost-effective because infants will be more likely to avoid HIV 
infection. Moreover, the incremental cost of Option B+ compared to other previous WHO 
recommendations for PMTCT decreased with an increase in the fertility rate and a decrease in 
the birth interval. [23]. 
 
4.0. DISCUSSION 
 
4.1. Implications for Policy 
Our overall findings suggest that life-long ART (Option B+) as a strategy for eliminating 
mother-to-child transmission of HIV provides good value for money. This strategy may be 
practically useful for developing countries in sub-Sahara Africa that tend to have high repeat 
pregnancy rates, limited access to CD4 testing, and have a long duration of breastfeeding by 
HIV-infected mothers. ,QOLQHZLWKWKHFXUUHQWµWHVW	WUHDWDOO¶UHFRPPHQGDWLRQ by WHO [9], 
the requirement that all HIV-positive women be put on life-long ART technically implies there 
ZLOOEHQRQHHGIRUµRSWLRQV¶IRU307&7LQSUDFWLFH,WWKHUHIRUHPDNHVKHDOWK-economic sense 
for policy-PDNHUVWRSULRULWL]HSUHJQDQWZRPHQ¶Vhealth care needs in resource-limited settings.  
The success of this strategy will largely depend on ability of decision-makers in resource 
limited countries to afford the cost of maintaining all HIV-infected women on lifelong ART.  
 
While each of the reviewed studies acknowledged the increased PMTCT cost associated 
with lifelong ART (Option B+), none reported on the health budget impact - an increasingly 
important requirement among payers in LMICs when considering new treatment options [35]. 
As argued by Marseille et al [36], even if an intervention is categorized as cost-effective based 
on its cost per DALY averted, that intervention may still not represent the best use of a 
FRXQWU\¶VKHDOWKEXGJHWRealizing that resources are limited, we believe it is imperative for 
future studies to report on the budget impact of different treatment options, and possibly show 
the Cost-Effectiveness Acceptability Curve (CEAC).  
 
Apart from its impact on reducing morbidity and mortality, including HIV transmission, 
evidence from this review further highlights that lifelong ART (Option B+) potentially attains 
greater gains on QALY and life-expectancy for both the mother and infant, including 
serodiscordant partners. Importantly, despite the initial increased cost for most resource-limited 
countries, early initiation of life-long ART is modelled as cost-saving in the long term as the 
initial cost is partly offset by subsequent reduced costs associated with improved SDWLHQWV¶
quality of life. This includes decreased hospitalization and increased productivity for those 
women in gainful economic sectors, and prevention of HIV transmission to subsequent 
children. The key policy directions for healthcare systems in resource-limited countries is to 
ensure uninterrupted ART services, availability of ARVs, adherence and retention in care [9]. 
Clearly, lifelong ART as a strategy for PMTCT may have little benefit in resource-limited 
countries if HIV-infected women do not adhere to their treatment regimen or are not retained 
in HIV care programs (loss to follow-up) [37, 38, 39]. Given the current situation where 
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different resources-limited African countries have different health system capacities, including 
different HIV epidemiology patterns, program quality and levels of ART coverage; additional 
interventions including human, infrastructure and fiscal resources may be required to maintain 
patients on ART in these settings. Recent evidence also suggests socio-cultural and 
technological (e.g. mobile phone-based) interventions may also come to the fore when making 
considerations to improve retention of postpartum women on ART care in Africa [40].  
 
4.2. Implications for Research 
 In as much as each of the studies reported on the cost-effective intervention, they did not 
report on the Willingness to Pay (WTP) threshold per DALY averted for each of the healthcare 
systems. This is especially important in settings where there are high co-payments for 
medicines as well as issues of affordability [41]. Although many resource-limited countries 
have explicitly referred to the WHO criteria [42] to set WTP thresholds for an intervention that 
is considered cost-effective if its ICER is less than three- times the annual national GDP per 
capita, and very cost-effective if the ICER is less than one GDP per capita, there is growing 
evidence that use of these criteria has major limitations [36].  
 
Although the reviewed studies considered the benefit of lifelong ART (Option B+) in terms 
of cost, life-years gained and averting infections to not only infants but also to serodiscordant 
partners among other outcomes, none of the studies looked at new infant infections averted, 
quality of maternal health outcomes and partner infections averted together, in addition to the 
ICER. Arguably, evaluating these three types of outcomes together would have potentially 
estimated the impact and cost-effectiveness of lifelong ART (Option B+) as a holistic outcome 
on the future health of mothers, infants and their partners.   
 
The simple deterministic model used by Gopalappa et al and Ciaranello et al often falls 
short of establishing at which point a woman enters the model and subsequent state transitions 
within the projected time horizon. Factors that may account for direct treatment disutility 
(DTD), for instance ARV toxicity resulting in discontinuation of ART in the initial phases, 
tend to be omitted in such a model.  Interestingly, Heath et al. [43] found that 58% of ARV 
toxicity accounted for discontinuation of first line cART regimen within 2 years of initiation. 
Since the models did not consider DTD, they may over or under-estimate the utility of the 
interventions as they assumed no patient inconvenience resulting from taking the treatment 
[44]. Thomson et al. [45] put across a notion that the total focus on subsequent health-related 
outcomes for an intervention results in missing some key attributes that patients may value. It 
is therefore important to take into consideration the process utility when considering attributes 
of a given intervention in order to ensure a precise result of cost-effectiveness. Moreover, since 
routine and continuous laboratory monitoring of patients¶ &' count, viral load and other 
relevant clinical parameters would be required while on lifelong ART, this additional cost was 
not comprehensively modeled in majority of the studies reviewed. This needs to be addressed 
in future studies to aid decision making especially in resource-limited countries. 
 
One limitation encountered with majority of the reviewed model-based studies is that cost 
analysis measures that aid healthcare decision-making were not robust. For instance, 
researchers would have done well to also conduct analysis of the Expected Value or Perfect 
Partial Information (EVPPI), which is a decision-theoretic measure of the cost of parametric 
uncertainty in decision-making used principally in health economic decision-making [43]. 
Another equally informative analytic measure of cost-effectiveness often used as alternative to 
ICER is the Incremental Net Monetary Benefit (INMB) that informs the willingness to Pay 
(WTP).  Ideally, the INMB helps in resolving well-known problems associated with ICER 
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when bootstrap replicates cover all four quadrants of the cost-effectiveness plane. Accordingly, 
researchers would confidently inform that the cost to derive the benefit from the intervention 
(lifelong ART) is less than the maximum amount that the decision-maker would be willing to 
pay for the benefit [46]. Understandably, the uptake and utilization of these complex 
measurements in cost-effectiveness analysis research was low.  
 
5.0. CONCLUSION 
The majority of the reviewed model-based studies favor lifelong ART (Option B+) to be 
a cost-effective intervention for PMTCT in resource-limited settings. However, the evidence 
remains weak for generalization to all other settings. This is largely because setting specificity 
for providing lifelong ART  to all pregnant women and breastfeeding mothers may differ 
significantly in each setting with regards to HIV epidemiology, fertility rates, coverage of HIV 
testing and treatment services, including health system practice of maternal and child 
healthcare. It is therefore practical that the roll out of lifelong ART strategy for eliminating 
mother-to-child HIV transmission, particularly in resource-limited settings, should be gradual 
and ensure that it conforms to the local resource availability required to meet total annual costs 
of investment into implementing the strategy, including treatment monitoring requirements in 
each setting. Our study further reveals that when making a decision on the adoption of lifelong 
ART strategy, health economic evaluations should be robustly undertaken. This means not only 
including sensitivity and cost analysis measures that aid healthcare decision-making in 
combination with the full domains of health system assessment in each setting, but also utilize 
more inclusive cost-effectiveness models that evaluate effects of lifelong ART compared to 
alternative strategies for HIV prevention among pregnant and breastfeeding women, their 
infants and partners.  
6.0. EXPERT COMMENTARY 
It is our contention that future cost-effectiveness studies and setting-specific economic 
evaluations should endeavor to assess the willingness and ability to pay of each setting, and 
include some form of budget impact analysis for each setting. Researchers should also 
endeavor to include an analysis of the Expected Value of Perfect Partial Information (EVPPI). 
This goes for all health-economic evaluations that end with recommendations for further 
research. EVPPI could also be used to decide on the inclusion of Direct Treatment Disutility 
(DTD). It would be interesting to investigate how the use of EVPPI and INMB would inform 
cost-effectiveness analyses of lifelong ART strategy for PMTCT in resource-limited countries. 
7.0. FIVE-YEAR VIEW 
In low- and middle-income countries, the pressure on limited resources in healthcare will 
continue to grow as new health technologies which are typically more expensive than current 
standards continue to be launched. This in turn calls for increased utilization of health-
economic evaluation tools to assist in ensuring efficiency as countries strive for universal 
access to quality and cost-effective healthcare. Consequently in the coming five years, health-
economic evaluations will continue to be more relevant in resource-limited settings. However, 
the limited availability of health economists to lead the process in some of the developing 
countriesFRXSOHGE\LQFUHDVHGSUDFWLFHRISD\HUV¶GHFLVLRQ-making that is based largely on 
cost-minimization analysis rather than cost-effectiveness analysis, may potentially frustrate 
efforts to fully complement clinical decisions with health economics. However, this can be 
partly addressed using capacity building strategies including establishing health technology 
assessment units within each health system.  
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In each setting, health programs and strategies require to be evaluated prior to 
implementation irrespective of sound clinical evidence. Consequently, if the assumptions are 
not robust enough, strategies such as lifelong ART may even potentially turn out to be 
economically catastrophic in some settings. At the rate we are moving in the global quest to 
attain zero HIV transmission there will be increased adoption of this strategy with the backing 
of the WHO. On the positive side, with recent evidence showing a life expectancy of ART-
treated HIV infected individuals being at par with non-infected individuals, it reinforces the 
evidence backing WKHFXUUHQWµtest and treat all¶ strategies recommended by WHO. In turn, this 
will accelerate implementation of lifelong ART as the strategy of choice for eliminating 
mother-to-child transmission of HIV in resource-limited countries. 
 
8.0. KEY ISSUES  
x Mother-to-child transmission of HIV, though virtually eliminated in developed 
countries, still remains a major challenge in low- and middle-income developing 
countries of sub-Saharan Africa which bear the huge brunt of the HIV/AIDS epidemic. 
x In order to achieve total elimination and prevention of mother-to-child transmission of 
HIV, universal access to treatment (ARVs) for every pregnant and breastfeeding 
woman has to be achieved in all LMICs. 
x Although PMTCT guidelines have evolved over the years from single dose nevirapine 
(sdNVP), dual ARV Therapy (Option A), short term HAART (Option B) to lifelong 
combination ART (Option B+) for HIV-infected pregnant woman, economic evaluation 
of these strategies must be a continuous process to ensure value for money evidence is 
generated when allocating the limited fiscal resources in resource-limited countries.  
x So far, based on the ICER, a number of model-based studies have found lifelong ART 
(Option B+) to be a cost-effective strategy for PMTCT especially in subsequent 
pregnancies. 
x The pressure on limited resources in the healthcare sector will continue to grow as 
health technologies continue. This in turn calls for increased utilization of robust and 
comprehensive health economic evaluation tools to assist in ensuring efficiency in 
resource use in LMICs. 
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